Literature DB >> 16733693

Pharmacokinetic-pharmacodynamic (PK-PD) modeling of cardiovascular effects of metoprolol in spontaneously hypertensive rats: a microdialysis study.

Christian Höcht1, Carla Di Verniero, Javier A W Opezzo, Guillermo F Bramuglia, Carlos A Taira.   

Abstract

The present work addressed possible alterations in the pharmacokinetics and the in vivo pharmacodynamic of metoprolol (MET) in spontaneously hypertensive (SH) rats and Wistar Kyoto (WKY) animals by means of the microdialysis technique. The correlation between MET unbound plasma concentrations and its pharmacological effects, such as heart rate and blood pressure change, was also examined in SH and WKY rats by the application of a PK-PD model. MET dialysate concentrations and its chronotropic and blood pressure effect were determined during 3 h after the administration of 3 and 10 mg.kg(-1) of the drug. A PK-PD model with a separate effect compartment was used to analyse the data. A good correlation between plasma MET concentrations and its hypotensive and chronotropic effect was found in all experimental groups. Although a greater maximal effect (E(max)) for the antihypertensive effect of MET was observed in SH rats (WKY: E(max): -17+/-1 mmHg; SH: E(max): -28+/-4 mmHg; P<0.05 versus WKY rats), no differences were found in the concentration yielding half-maximal response (IC(50)) comparing SH (IC(50): 583+/-146 ng x ml(-1)) and WKY animals (IC(50): 639+/-187 ng x ml(-1)). The bradycardic effect of MET was greater in SH rats (E(max): -29+/-1%, P<0.05 versus WKY rats) than in WK animals (E(max): -22+/-2%), but no differences were observed in the IC(50) comparing both experimental groups (WKY: IC(50): 187+/-53 ng x ml(-1); SH: IC(50): 216+/-62 ng x ml(-1)). Pharmacokinetic analysis shows that the volume of distribution of MET was greater in SH rats (Vd: 3.4+/-0.5 l, P<0.05 versus WKY rats) with regard to Wistar Kyoto (WKY) animals (Vd: 1.9+/-0.2 l). The results suggest that the pharmacokinetic behaviour of metoprolol are modified in SH rats, resulting in an increased volume of distribution. A greater maximal efficacy to the hypotensive effect of metoprolol was observed in SH rats, suggesting participation of beta-adrenoceptors in the maintenance of the hypertension. Also, a greater chronotropic response to metoprolol was found in the hypertensive group compared with WKY animals, suggesting that, at least in part, the greater cardiac effect of metoprolol explained the enhanced hypotensive response of the beta blocker in the SH animals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16733693     DOI: 10.1007/s00210-006-0078-x

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  35 in total

Review 1.  Clinical relevance of optimal pharmacokinetics in the treatment of hypertension.

Authors:  P A Meredith
Journal:  J Hypertens Suppl       Date:  1997-12

2.  Pharmacokinetic study of methyldopa in aorta-coarctated rats using a microdialysis technique.

Authors:  J A Opezzo; C Höcht; C A Taira; G F Bramuglia
Journal:  Pharmacol Res       Date:  2001-02       Impact factor: 7.658

3.  Relation of propranolol plasma level to beta-blockade during oral therapy.

Authors:  R Zacest; J Koch-Weser
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

4.  Adipocyte responsiveness to norepinephrine in spontaneously hypertensive rats.

Authors:  G E Chiappe de Cingolani
Journal:  Metabolism       Date:  1988-04       Impact factor: 8.694

5.  The effects of a cardioselective (metoprolol) and a nonselective (propranolol) beta-adrenergic blocker on the response to dynamic exercise in normal men.

Authors:  J Sklar; G D Johnston; P Overlie; J G Gerber; H L Brammell; J Gal; A S Nies
Journal:  Circulation       Date:  1982-05       Impact factor: 29.690

6.  Concentration-effect relationship of l-propranolol and metoprolol in spontaneous hypertensive rats after exercise-induced tachycardia.

Authors:  L Brynne; M O Karlsson; L K Paalzow
Journal:  J Pharmacol Exp Ther       Date:  1998-09       Impact factor: 4.030

7.  Pathophysiologic and pharmacokinetic determinants of the antihypertensive response to propranolol.

Authors:  M Esler; A Zweifler; O Randall; V DeQuattro
Journal:  Clin Pharmacol Ther       Date:  1977-09       Impact factor: 6.875

8.  Pharmacokinetic-pharmacodynamic properties of metoprolol in chronic aortic coarctated rats.

Authors:  Christian Höcht; Carla Di Verniero; Javier A W Opezzo; Carlos A Taira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-22       Impact factor: 3.000

9.  Catecholamine-stimulated lipolysis in adipocytes of spontaneously hypertensive rats.

Authors:  J A Spitzer; A H Burns; P J O'Malley
Journal:  Biochem Med       Date:  1985-08

10.  Differential development of vascular and cardiac hypertrophy in genetic hypertension. Relation to sympathetic function.

Authors:  M A Adams; A Bobik; P I Korner
Journal:  Hypertension       Date:  1989-08       Impact factor: 10.190

View more
  6 in total

1.  Prior β-blocker treatment decreases leukocyte responsiveness to injury.

Authors:  Laurel A Grisanti; Claudio de Lucia; Toby P Thomas; Aron Stark; John T Strony; Valerie D Myers; Remus Beretta; Daohai Yu; Celestino Sardu; Raffaele Marfella; Erhe Gao; Steven R Houser; Walter J Koch; Eman A Hamad; Douglas G Tilley
Journal:  JCI Insight       Date:  2019-03-28

2.  Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

Authors:  Christopher Louizos; Jaime A Yáñez; M Laird Forrest; Neal M Davies
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

3.  Enantioselective pharmacokinetic and pharmacodynamic properties of carvedilol in spontaneously hypertensive rats: focus on blood pressure variability.

Authors:  Facundo Martín Bertera; Julieta Sofía Del Mauro; Diego Chiappetta; Ariel Héctor Polizio; Fabián Buontempo; Carlos Alberto Taira; Christian Höcht
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-11-03       Impact factor: 3.000

4.  Metoprolol impairs resistance artery function in mice.

Authors:  Mostafa H El Beheiry; Scott P Heximer; Julia Voigtlaender-Bolz; C David Mazer; Kim A Connelly; David F Wilson; W Scott Beattie; Albert K Y Tsui; Hangjun Zhang; Kabir Golam; Tina Hu; Elaine Liu; Darcy Lidington; Steffen-Sebastian Bolz; Gregory M T Hare
Journal:  J Appl Physiol (1985)       Date:  2011-07-28

5.  Effect of nebivolol on beat-to-beat and short-term blood pressure variability in spontaneously hypertensive rats.

Authors:  Facundo Martín Bertera; Julieta Sofía Del Mauro; Ariel Héctor Polizio; Diego Chiappetta; Carlos Alberto Taira; Christian Höcht
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-05-09       Impact factor: 3.000

6.  Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint.

Authors:  T J van Steeg; J Freijer; M Danhof; E C M de Lange
Journal:  Br J Pharmacol       Date:  2007-04-10       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.